Xeris Biopharma Holdings annual operating expenses
2020
2021
2022
2023
2024
2025
Xeris Biopharma Holdings Operating Expenses Growth & History (XERS)
Xeris Biopharma Holdings's operating expenses was $266.9M for fiscal 2025.
View full Xeris Biopharma Holdings company overviewXeris Biopharma Holdings annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $266.9M | $30.2M | +12.77% |
| 2024 | 2024-12-31 | $236.7M | $28.8M | +13.85% |
| 2023 | 2023-12-31 | $207.9M | $15.7M | +8.19% |
| 2022 | 2022-12-31 | $192.2M | $27.4M | +16.66% |
| 2021 | 2021-12-31 | $164.7M | $60.8M | +58.44% |
| 2020 | 2020-12-31 | $104.0M | — | — |
Xeris Biopharma Holdings quarterly operating expenses
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $86.9M | $19.9M | +29.63% |
| Q1 2026 | 2026-03-31 | $75.2M | $12.0M | +18.99% |
| Q4 2025 | 2025-12-31 | $69.0M | $10.6M | +18.17% |
| Q3 2025 | 2025-09-30 | $67.6M | $488,000 | +0.73% |
| Q2 2025 | 2025-06-30 | $67.1M | $10.8M | +19.21% |
| Q1 2025 | 2025-03-31 | $63.2M | $8.3M | +15.17% |
| Q4 2024 | 2024-12-31 | $58.4M | — | — |
| Q3 2024 | 2024-09-30 | $67.2M | $13.9M | +26.16% |
| Q2 2024 | 2024-06-30 | $56.3M | $2.3M | +4.20% |
| Q1 2024 | 2024-03-31 | $54.9M | — | — |
| Q3 2023 | 2023-09-30 | $53.2M | $4.7M | +9.75% |
| Q2 2023 | 2023-06-30 | $54.0M | $9.8M | +22.08% |
| Q4 2022 | 2022-12-31 | $48.3M | −$24.6M | −33.74% |
| Q3 2022 | 2022-09-30 | $48.5M | $16.3M | +50.65% |
| Q2 2022 | 2022-06-30 | $44.2M | $9.5M | +27.47% |
| Q1 2022 | 2022-03-31 | $51.1M | $26.2M | +105.12% |
| Q4 2021 | 2021-12-31 | $72.9M | — | — |
| Q3 2021 | 2021-09-30 | $32.2M | $11.8M | +58.14% |
| Q2 2021 | 2021-06-30 | $34.7M | — | — |
| Q1 2021 | 2021-03-31 | $24.9M | — | — |
| Q3 2020 | 2020-09-30 | $20.4M | — | — |
Xeris Biopharma Holdings operating expenses trends
Over the last five fiscal years, Xeris Biopharma Holdings's operating expenses increased from $104.0M to $266.9M, a change of $163.0M. The latest reported quarter, Q2 2026, shows $86.9M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xeris Biopharma Holdings source filings ↗